Company Overview

Cibus, Inc. (NASDAQ: CBUS) is an agricultural biotechnology company focused on developing and commercializing plant traits for major row crops using gene-editing and precision breeding technologies. The company operates within the agricultural biotechnology and seed-trait industries, with an emphasis on improving crop productivity, herbicide tolerance, disease resistance, and sustainability-related characteristics. Its core commercial focus has centered on traits for crops such as canola, rice, soybean, and wheat.

The company’s primary revenue drivers have historically included trait licensing arrangements, collaboration agreements, and technology development activities rather than large-scale seed sales. Cibus positions itself as a technology-driven trait developer that works with seed companies and agricultural partners to integrate proprietary traits into commercial germplasm. A key element of its strategy is the use of its proprietary gene-editing platform, often referred to in company materials as the Rapid Trait Development System (RTDS) and related high-throughput trait development capabilities. Cibus traces its origins to biotechnology research operations founded in the early 2000s and later became a publicly traded company through a business combination involving Calyxt, Inc. and legacy Cibus operations.

Business Operations

Cibus conducts operations primarily through its crop trait development platform and associated intellectual property portfolio. The company’s business activities include identifying commercially valuable crop traits, applying gene-editing technologies to create those traits, conducting field and regulatory testing, and partnering with seed companies for commercialization. Public filings have emphasized crop trait programs in canola and rice, including herbicide tolerance traits and productivity-enhancing characteristics. The company’s technology infrastructure includes proprietary gene-editing methodologies, plant breeding capabilities, trait screening systems, and associated genomic data assets.

Operations are centered in the United States, with research and development activities historically conducted from facilities in San Diego, California, as well as additional operational presence in Canada. Cibus has pursued collaborative relationships with agricultural and seed-sector companies to expand commercialization pathways for its traits. The company has also disclosed partnerships and licensing relationships connected to seed development and trait deployment, although some commercial terms and long-term revenue impacts remain dependent on regulatory approvals, farmer adoption, and partner execution. Data regarding the full current scope of joint ventures or active commercialization agreements is inconclusive based on available public sources.

Strategic Position & Investments

Cibus has positioned itself around the growing demand for precision breeding technologies and gene-edited crop traits that may, in certain jurisdictions, face different regulatory pathways than transgenic genetically modified organisms. Its strategic direction has focused on accelerating trait development timelines, expanding trait pipelines across multiple crops, and establishing licensing-based commercial models with seed industry participants. The company has publicly highlighted the scalability of its trait development platform and its ability to target multiple crop characteristics simultaneously.

A significant strategic development was the merger transaction involving Calyxt, Inc., which combined complementary plant biotechnology assets and public-market infrastructure. Cibus has continued investing in research and development tied to next-generation crop traits, including herbicide tolerance, nitrogen-use efficiency, and productivity enhancement programs. The company has also emphasized automation, computational biology, and high-throughput breeding technologies as part of its broader innovation strategy. While management has discussed opportunities in sustainable agriculture and climate-resilient crop systems, the long-term commercial impact of these initiatives remains dependent on regulatory developments and market adoption.

Geographic Footprint

Cibus is headquartered in San Diego, California, and maintains operations primarily in North America, with commercial and research interests extending into international agricultural markets. The company’s crop programs are designed for globally significant agricultural regions, including markets in North America, South America, and parts of Asia-Pacific, particularly where canola, rice, soybean, and wheat production are strategically important.

The company’s international reach is driven largely through licensing opportunities, regulatory engagement, seed-industry partnerships, and crop trait applicability rather than broad physical infrastructure ownership across multiple countries. Cibus has also maintained operational ties to Canada, particularly in connection with canola trait development and agricultural testing activities. Public disclosures indicate an international commercialization orientation, although detailed country-level revenue concentration data remains limited in publicly available materials.

Leadership & Governance

Cibus leadership has emphasized accelerating crop innovation through scalable gene-editing technologies and collaborative commercialization models within the global seed industry. Governance and strategic oversight are structured around biotechnology commercialization, agricultural science, and capital markets experience. Founder involvement has historically played a meaningful role in shaping the company’s technology and strategic direction.

Key executives identified in public filings and company disclosures include:

• Rory Riggs – Co-Founder and Executive Chair
• Peter Beetham, Ph.D. – Co-Founder and Interim Chief Executive Officer
• Greg Gocal, Ph.D. – Co-Founder and Chief Scientific Officer
• Sharon Corcoran – Interim Chief Financial Officer

Certain executive roles and leadership assignments may have changed after the most recent publicly available filings. Where discrepancies existed across public disclosures, the most consistently reported information was prioritized.